FDA approves Cologuard Plus and Shield blood tests for colorectal cancer screening.

The FDA has approved two new colorectal cancer screening tests: Cologuard Plus and the Shield blood test. Cologuard Plus, a stool DNA test, shows 95% cancer sensitivity and aims to encourage screenings among adults 45 and older at average risk. The Shield test, a blood test, detects 83% of colorectal cancers but only 13% of dangerous polyps. Both tests offer less invasive alternatives to traditional colonoscopy, potentially increasing screening rates.

October 07, 2024
7 Articles